Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pogona LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, which means the company's current prosecution activity is entirely centralized. With only 1 pending action, the company's immediate success in obtaining patent rights depends on the evaluation of this examiner. Practitioners should prioritize a direct and clear dialogue with this individual to resolve any outstanding rejections.
The activity is limited to 1 distinct art unit, aligning with the 1 examiner. This narrow focus simplifies the administrative requirements for the company, as it only needs to comply with the specific practices of 1 specialized group. Practitioners can tailor their arguments specifically to the standards and precedents of this 1 art unit. This concentration of resources can lead to a more efficient prosecution process compared to portfolios spread across multiple units.
JACKSON-TONGUE, LAKIA J is the busiest examiner for this portfolio, with 1 pending office action. As this is the only active matter, this examiner manages the company's entire pending workload. This level of concentration highlights the importance of the relationship between the company and this specific examiner in the current prosecution cycle. The outcome of the company's current efforts rests entirely with this 1 examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19072186 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19072186 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | 1645 | §102Other | Non-Final OA | — | Pending | Mar 06, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPogona LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lakia J Jackson-Tongue has the most, with 1 of Pogona LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
